A subscription to JoVE is required to view this content. Sign in or start your free trial.
Magnetic resonance could offer real-time monitoring of the position and temperature of focused ultrasound in thermal ablation for painful bone metastases, regardless of cancer type or previous local treatments. Our innovative method of quality assurance could facilitate the application of this effective and safe treatment.
Bones are one of the most common sites of cancer metastasis, which usually causes pain and impairs quality of life. Radiation therapy combined with opioids is the standard treatment for painful bone metastases. This treatment achieves effective pain control in 60−74% of patients, but limited treatment choices with limited benefits are available for recurrent or residual painful bone metastases after radiotherapy. More than 40% of patients still experience moderate to severe bone pain after reirradiation. Magnetic resonance-guided focused ultrasound (MRgFUS) combines high-intensity focused ultrasound, which achieves thermal ablation of bone metastases and subsequent pain reduction, with real-time magnetic resonance (MR) thermometry to monitor the temperature of anatomic MR images, with an accuracy of 1 °C, spatial resolution of 1 mm, and temporal resolution within 3 s. As well as being increasingly used clinically for controlling metastatic bone pain, the use of MRgFUS for other diseases has also been tested. However, the use of MR software as a thermometer is the only technique available to verify the accuracy of the software and assure energy delivery. Here, we describe an efficient method of quality assurance we developed for thermal detection and energy delivery before each MRgFUS treatment and also propose a modified workflow to expedite the treatment course as well as to reduce patients' pain during the procedure.
Bones are one of the most common sites of cancer metastasis, which usually causes pain and impairs quality of life. Radiation therapy (RT) combined with opioids is the standard treatment for painful bone metastases. This treatment achieves effective pain control in 60−74% of patients1. However, limited treatment choices are available for recurrent or residual metastatic bone pain after RT. Reirradiation, surgical intervention, percutaneous cryoablation, or radiofrequency ablation and increased doses of systemic opioids and analgesics are options with limited indications and usually with side effects. Moreover, these secondary treatments h....
Taipei Medical University Joint Institutional Review Board approval was obtained for this study.
NOTE: The same protocol, validated in Kao et al.11, has been used to treat 138 cases between 2015 and 2019. The inclusion criteria for treatment enrollment were 1) the presence of a solitary distinguishable painful bone metastasis; 2) no administration of previous local therapy to the targeted bone lesion; and 3) the ability to access the targeted bone lesion with MRgFUS (
A 68-year-old male patient was diagnosed with hepatocellular carcinoma (HCC) in October 2012. He received a left lobectomy on October 18, 2012, and pathology reported an 8.8 cm HCC. After operation, he experienced lower back pain and soreness, and an MRI on November 2, 2012 revealed a large metastatic mass involving the left sacrum, ilium, and gluteal soft tissue. Because of tumor compression and pain reaching 6 points on the visual analogue scale (VAS), he received RT with 45 Gy in 15 fr.......
Several studies have demonstrated that MRgFUS is safe and efficient for controlling pain from recurrent or residual bone metastases after RT12,13. For 64.3-72.0% of patients, metastatic bone pain persists after RT and opioids. Studies have also determined MRgFUS has limited toxicity and a tolerable treatment course.
MRgFUS received approval for use in metastatic bone pain in 2011 by the Conformité Européenne and in 2012 by th.......
The authors thank Renyi Wang, medical physicist, for her help with investigating DQA.
....Name | Company | Catalog Number | Comments |
1L degasseed water pouch | InSightec | ASM001480 | for good ultrasound beam transmission |
CT scan | Philips | Brilliance Big Bore 16 Slice CT, 7387 | Acquire CT images for positioning |
EXABLATE | InSightec | EXABLATE 2000 | System for non-invasive tumor ablation through Focal Ultrasound (FUS) treatment under Magnetic Resonance (MR) guidance |
Gel Pad ASSY | InSightec | SET999014 | Transmission gel pad for single Body treatment. |
MR scan | GE | HDxT | Acquire MR images for contouring and planning |
MRI contrast | Guerbet | Dotarem | Enhance MR for acquiring images |
Patient accessory kit | InSightec | SET000016 | clinical applications single use treatment kit |
Patient plastic drape | InSightec | DTP000067 | Cover the panel of ultrasound transducer. Deposible, hygiene use |
Pelvic RF coil | GE | ASM000956 | Enhance MR for acquiring images |
phantom | ATS Labs ATS Labs Inc | Model TxS-100 | for calibration |
ultrasound transmission gel | InSightec | SET000885 | gel for calibration prior MR-guided FUS treatment |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved